AlphAIAlphAI — Financial news for AI agents
investing.comOCT 23 min read$CGEM

H.C. Wainwright reiterates Cullinan Oncology stock rating on NDA filing

H.C. Wainwright reiterated a Buy rating and $35 price target for Cullinan Oncology (CGEM) after its rolling NDA submission for zipalertinib. The stock is up 153% over a year, trading at $14.53. Positive Phase 3 trial results showed improved outcomes for zipalertinib plus chemotherapy in NSCLC. Approval could trigger milestone payments. CGEM has strong cash position but high annual burn rate.

Original reporting
investing.com
Published Oct 2, 2026, 11:48 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 2, 2026, 11:57 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefRegulation
Primary signal
$CGEM
Bullish
high confidence
Mentioned
$CGEM
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$CGEMBullishMed
01

Why it matters

The filing and analyst reaffirmation provide fresh positive momentum, but safety data and regulatory review remain uncertainties.

02

Market read

The news could trigger short-term buying pressure in CGEM and influence sentiment in the oncology biotech niche.

03

What to watch

Potential safety concerns from Grade 3+ adverse events could delay approval.

Relevance 8/10Novelty 8/10Timing: same-day release

Background

Cullinan Oncology (CGEM) is a Nasdaq-listed biotech developing zipalertinib for EGFR Ex20Ins+ NSCLC. The rolling NDA filing follows Phase 3 trial data showing improved response rates and progression-free survival.

Company-level read

Ticker impact

$CGEMBullishHigh confidence
Context

H.C. Wainwright reiterated a Buy rating and $35 price target after Cullinan Oncology announced a rolling NDA submission for zipalertinib.

Expected impact

likely upside as market prices in the prospect of approval and strong trial data

Evidence & confidence

The new NDA filing is a primary disclosure for a biotech, and the analyst upgrade adds fresh positive catalyst.

Market effects

Sector

Positive signal for the oncology biotech sector, may lift peers with similar FDA pipelines.

Regional

US biotech market may see modest gains as investors react to the filing.

Global

Limited to biotech investors; no broad market effect.

Counterpoint

What could challenge this read

If the FDA raises concerns, the stock could face a sharp correction despite the rating.

Key entities

  • company
    Cullinan Oncology Inc.

    Biotech developing zipalertinib, subject of the NDA filing.

  • analyst
    H.C. Wainwright

    Equity research firm reiterating Buy rating and $35 price target.

Read at source← All news

Related articles

OCT 2
$CGEMMedAI 8/10

Cullinan Therapeutics starts NDA submission for zipalertinib plus chemo under FDA RTOR

Cullinan Therapeutics began submitting an NDA to the FDA for zipalertinib combined with chemotherapy in first-line EGFR exon 20 insertion NSCLC under the RTOR program. The submission is based on the Phase 3 REZILIENT3 trial, which met its primary endpoint. The company expects to complete the submission by year-end 2026. Zipalertinib has FDA Breakthrough Therapy designation, and a separate NDA for monotherapy has a PDUFA date of Feb 27, 2027.

tradingview.com1 min
OCT 2
$CGEMMedAI 9/10

Cullinan's Zipalertinib Combination Heads To FDA After Positive Phase 3 Lung Cancer Trial

Cullinan Therapeutics (CGEM) submitted a New Drug Application to the FDA for zipalertinib in combination with chemotherapy to treat a specific type of lung cancer. The submission is under the FDA's Real-Time Oncology Review program and is supported by positive Phase 3 trial data showing improved progression-free survival. The company expects to complete the submission by the end of 2026. CGEM's stock closed at $14.53, down 5.34%.

rttnews.com2 min
OCT 1
$CGEMHighAI 8/10

Cullinan initiates FDA filing for lung cancer drug zipalertinib

Cullinan Therapeutics (CGEM) initiated an FDA filing for zipalertinib, a lung cancer drug, in combination with chemotherapy. The Phase 3 trial met its primary endpoint, showing improved progression-free survival. The company expects to complete the NDA submission by year-end 2026 and could receive $130 million in milestones upon approvals. Zipalertinib is being developed with Taiho Oncology and Taiho Pharmaceutical.

investing.com2 min
OCT 1
$CGEMMedAI 8/10

Cullinan Therapeutics, Inc. (CGEM): New Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA…

Cullinan Therapeutics, Inc. (CGEM) filed an SEC Form 8-K — Other Events. Exhibit 99.1 New Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA Real-Time Oncology Review Program In the Phase 3 REZILIENT3 study, zipalertinib combination therapy demonstrated long

SEC EDGAR 8-K2 min